MajestEYE

What MajestEYE does

MajestEYE is a Tunisia-headquartered AI and data analytics vendor that builds proprietary advanced analytics software applied across three primary verticals: Healthcare & Pharma, Financial Services, and Government. Its flagship product, DrugEYE™, performs off-laboratory functional characterization of microorganism genes from genomic inputs and shortlists candidate drug molecules, with company-reported use during the COVID-19 response to predict SARS-CoV-2 gene functions months ahead of wet-lab results. Complementary products include dynamic customer segmentation with next-best-action recommendation, intelligent fraud detection for transaction monitoring, intelligent SME credit limit assignment, and predictive SME creditworthiness scoring, plus a government-focused big-data analytics and decision-support suite.

The platform is delivered through a combination of direct enterprise sales (quote-based subscription, 'Request a demo' funnel) and channel partners — most notably FiSer Consulting for European financial institutions — with go-to-market further amplified through accelerator memberships including British Telecom's Innovation Martlesham, the JICA NINJA competition in Japan, and the Africa By Incubme program in Algeria. Customer logos span international development institutions (UNDP, IFC, JICA), telecom (Djezzy, OEF), retail (Gourmandise), and consulting (TrustWorksGlobal, IM Associates), though public financial disclosure on revenue, contract sizes, and funding is absent. The company positions itself as AI-native but at modest scale, with 11-50 employees and an in-house Data Science Academy used as a recruiting and capacity-building lever.

Operationally, MajestEYE is privately held, founders-led (Jihed Hannachi as Co-founder/Business Development Lead and Madjda Gheribi as Pre-sales Engineer), and pursues an internationally distributed footprint with a Tunis headquarters, an Algiers regional presence, and an engineering/R&D seat at BT's AdastralPark in Ipswich, UK. Its business model is enterprise software and AI services sold on a subscription/quoted basis to mid-sized and institutional buyers, supplemented by accelerator-driven visibility and channel-sourced demand rather than disclosed venture funding.

Name

MajestEYE

Legal name

MajestEYE

Website

https://majesteye.com

Company type

Private

Operating status

Operating

Headcount range

11–50 employees

Short description

MajestEYE is a Tunisia-based AI and data analytics vendor that sells proprietary enterprise solutions — including the DrugEYE drug-discovery platform, fraud detection, SME credit analytics, and customer segmentation — to clients in Healthcare & Pharma, Financial Services, and Government sectors across Europe, North Africa, and Asia.

Ownership category

akta.pro rank

Headquarters

HQ city

Jendouba

HQ country

Tunisia

HQ region

Africa

Offices3 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations

Revenue model

1. AI & Analytics Solutions: Enterprise AI and data analytics solutions sold to financial institutions, healthcare organizations, and government agencies. Revenue appears to come from solution licensing and implementation services.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Core offering

MajestEYE develops and licenses a proprietary advanced analytics technology platform that applies AI, machine learning, deep learning, and computer vision to deliver vertical-specific data-driven solutions. Its standalone healthcare product DrugEYE™ performs off-laboratory drug discovery by characterizing the functional behaviour of emerging organism genes and predicting long-term human-body impacts from genomic data. Across financial services, the company offers dynamic customer segmentation, intelligent fraud detection, intelligent SME credit limit, and predictive SME creditworthiness modules, while government customers receive big-data decision-support solutions.

Product overview

MajestEYE is an AI-driven data analytics company offering a proprietary advanced analytics technology platform with sector-specific solutions. The portfolio includes DrugEYE™ as the core healthcare/pharma product for data-driven drug discovery, complemented by financial services solutions (Dynamic customer segmentation, Intelligent SME credit limit, Intelligent fraud detection) and government solutions (Predictive SME creditworthiness, Big Data Analytics & Decision solutions). The platform leverages machine learning, deep learning, and computer vision technologies to enable the transition to data-driven business models across Healthcare & Pharma, Financial Services, and Government verticals.

Differentiator

Problem solved

Functional benefit

Brands

• DrugEYE™: Data-driven drug discovery solution that provides foreknowledge about emerging organisms (viruses, bacteria) immediately after detection. Features include functional characterization of organism genes, prediction of long-term impacts on human body, and shortlisting of candidate molecules for drug discovery.

Products and services

• DrugEYE™ Data-driven drug discovery solution for pharmaceutical companies, research laboratories, and health authorities; provides foreknowledge about emerging organisms immediately after detection by generating functional gene characterization off-laboratory using genomic data, predicting long-term human-body impacts, and shortlisting candidate molecules.
• Dynamic Customer Segmentation AI-inferred customer segmentation solution for enterprise customers that anticipates customer needs by modelling behaviour and preferences, with automatic updates identifying emerging behavioural patterns and a recommendation engine for up-selling, cross-selling, Next Best Opportunities, Next Best Actions, and best channel selection.
• Intelligent Fraud Detection Real-time fraud detection solution for financial institutions that performs continuous and automatic modelling of fraud patterns with preventive detection at the transaction level, automatic identification of potentially fraudulent transactions, and a fraud knowledge base for objective data-driven policymaking.
• Intelligent SME Credit Limit SME lending solution that reduces turnaround time and enriches lending decision criteria through automatic credit limit definition and reassessment engine, with credit limit rule generation and prescription/recommendation capabilities for credit limit management.
• Predictive SME Creditworthiness Predictive creditworthiness solution that introduces timeliness and nuance in classifying healthy companies, with a credit incident prediction engine, credit losses patterns and rules generation to inform credit policy, an up-to-date SME risk knowledge base, and a 360-degree view of SMEs.
• Big Data, Analytics & Decision Solutions Government and public-sector big-data analytics solutions that collect and analyse open data from various sources to support evidence-based policymaking, including tax optimization, service delivery improvement, and better policy decisions through analysis of large volumes of time-series data.

Quantifiable outcome

• DrugEYE predicted SARS-CoV-2 virus genes' functions 3 months ahead of first wet laboratories' results with 100% accuracy
• +1 more outcomes

Named customers8 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature5 records

Partnerships

Five partnerships are on record, tiered core, flagship and minor.

• Africa By Incubme ProgramcoreStrategic or Co-development Partner · 1 December 2021Acceleration program facilitating MajestEYE's expansion into Algerian and African markets. Provides coaching, mentoring, market introduction, and access to emerging markets for technology companies in Life Sciences, Financial Services, and Government sectors.
• FiSer ConsultingcoreChannel Partner/ Reseller/ Distributor · 1 November 2021Strategic partnership combining MajestEYE's AI technology with FiSer's consulting expertise for financial services transformation. FiSer uses client networks to promote MajestEYE solutions, manages relationships, evaluates solution fit, and creates joint thought leadership content including presentations, podcasts, webinars, and blogs.
• JICA (Japan International Cooperation Agency)flagshipStrategic or Co-development Partner · 1 February 2021Selected as top 10 most innovative African startup for NINJA competition to present DrugEYE solution to 3,000 Japanese companies. Provides international market access and validation for MajestEYE's technology in Japanese market.
• British Telecom Innovation Martlesham IncubatorcoreStrategic or Co-development Partner · 1 February 2021Admitted to BT incubator cluster at AdastralPark headquarters alongside 140+ tech companies including Cisco, Huawei, Accenture, Intel, Ericsson. Provides access to personalized BT expert support, investor meetings, and partnership opportunities.
• NGOs and Non-Governmental OrganizationsminorOthers · 1 January 2021Commitment to making technology accessible for NGOs through new solutions specifically developed for nonprofit organizations to leverage data for action and impact.

Scale indicators4 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Palantir Technologies: Large-scale data analytics and AI platform serving governments, financial institutions, and pharma with decision-support solutions. Comparable to MajestEYE's Big Data Analytics & Decision solutions and fraud/credit analytics offerings at an enterprise scale.
• DataRobot: Enterprise AI/ML platform offering predictive modeling, anomaly detection, and recommendation engines. Comparable to MajestEYE's predictive SME credit, fraud detection, and dynamic segmentation modules as part of a broader analytics suite.

Regional players

• InstaDeep: Tunisia-headquartered AI company with strengths in biotech, genomics, and enterprise ML, acquired by BioNTech. Closest regional peer to MajestEYE given shared North African origin, similar genomic/AI capabilities, and overlapping pharma and enterprise customer base.

Direct peers

• Insilico Medicine: Pioneer in AI-driven drug discovery using deep learning for target identification, molecule design, and clinical prediction. Most directly comparable to MajestEYE on the DrugEYE value proposition of in silico drug discovery ahead of wet-lab validation.
• Exscientia: AI-native pharmatech company using machine learning to accelerate small-molecule drug discovery and design. Comparable to MajestEYE in applying AI/ML end-to-end across the drug discovery workflow.
• BenevolentAI: AI platform for drug discovery that ingests biomedical knowledge graphs to identify novel targets and therapies. Direct overlap with DrugEYE's AI-driven target identification and molecule prioritization approach.
• Atomwise: Applies AI to predict binding affinity and identify promising drug candidates from massive virtual libraries. Direct overlap with DrugEYE's in silico candidate molecule shortlisting capability.
• Recursion Pharmaceuticals: Combines high-throughput biology with AI/ML to discover and develop drug candidates at scale. Comparable to MajestEYE's integration of AI with biological data for target ID and drug discovery.

Emerging players

• H2O.ai: Provider of open-source and enterprise AI/ML platforms for predictive analytics, anomaly detection, and recommendation use cases. Comparable to MajestEYE's fraud detection, credit scoring, and segmentation products delivered to financial institutions and government.
• InVivo AI: Early-stage AI platform applying machine learning to preclinical drug discovery and candidate prioritization. Comparable to DrugEYE's narrower scope of computational drug discovery and molecule shortlisting.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/majesteye
• Facebookfacebook.com/majesteye
• LinkedInlinkedin.com/company/majesteye

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MajestEYE